Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyperproliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented.

A clinical phase IIa study in patients with mild-moderate psoriasis has been scheduled to start in January 2008 to reconfirm the pre-clinical findings and development of treatments for other skin disorders are currently being planned.